Research ExplorerPublicationsCD151 expression is frequent but unrelated to clinical outco...

CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.

Standard

CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. / Nienstedt, Julie Cläre; Gröbe, Alexander; Lebok, Patrick; Büscheck, Franziska; Clauditz, Till Sebastian; Simon, Ronald; Heumann, Asmus; Sauter, Guido; Möbius, Christoph; Münscher, Adrian; Knecht, Rainald; Blessmann, Marco; Heiland, Max; Pflug, Christina; kiehn, saskia.

In: CLIN ORAL INVEST, Vol. 21, No. 5, 06.2017, p. 1503-1508.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Nienstedt, JC, Gröbe, A, Lebok, P, Büscheck, F, Clauditz, TS, Simon, R, Heumann, A, Sauter, G, Möbius, C, Münscher, A, Knecht, R, Blessmann, M, Heiland, M, Pflug, C & kiehn, S 2017, 'CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.', CLIN ORAL INVEST, vol. 21, no. 5, pp. 1503-1508. https://doi.org/10.1007/s00784-016-1911-3

APA

Nienstedt, J. C., Gröbe, A., Lebok, P., Büscheck, F., Clauditz, T. S., Simon, R., Heumann, A., Sauter, G., Möbius, C., Münscher, A., Knecht, R., Blessmann, M., Heiland, M., Pflug, C., & kiehn, S. (2017). CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. CLIN ORAL INVEST, 21(5), 1503-1508. https://doi.org/10.1007/s00784-016-1911-3

Vancouver

Nienstedt JC, Gröbe A, Lebok P, Büscheck F, Clauditz TS, Simon R et al. CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. CLIN ORAL INVEST. 2017 Jun;21(5):1503-1508. https://doi.org/10.1007/s00784-016-1911-3

Bibtex

@article{c83bcf59803d4ea79fcca3ca3294dd86,
title = "CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.",
abstract = "ObjectivesCD151 is a plasma membrane protein belonging to the tetraspanin family. CD151 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types. The present study aims to investigate the prognostic relevance of immunohistochemical CD151 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methodsTissue microarray (TMA) sections containing samples from 667 cancers of oral cavity, oro- and hypopharynx and larynx, for which follow-up data were available, were analyzed for CD151 expression by immunohistochemistry.ResultsMembranous CD151 immunostaining was recorded in 269 (60.3 %) of 446 analyzable cases. Staining was considered weak in 129 (28.9 %), moderate in 98 (22.0 %), and strong in 42 (9.4 %) of cancers. CD151 expression was unrelated to histological grade, tumor stage, nodal status, or surgical margin. There was a tendency towards a somewhat lower prevalence of CD151 expression in tumors of the oral cavity (52.9 % positive) as compared to cancers of the oro-hypopharynx (62.1 %) and larynx (63.3 %; p = 0.0100). CD151 expression had no impact on patient survival.Clinical relevanceIn summary, immunohistochemical analysis of CD151 lacks prognostic utility in HNSCC. The high prevalence of CD151 expression in HNSCC emphasizes its putative relevance as a therapeutic target for further development of anti-CD151 drugs.",
author = "Nienstedt, {Julie Cl{\"a}re} and Alexander Gr{\"o}be and Patrick Lebok and Franziska B{\"u}scheck and Clauditz, {Till Sebastian} and Ronald Simon and Asmus Heumann and Guido Sauter and Christoph M{\"o}bius and Adrian M{\"u}nscher and Rainald Knecht and Marco Blessmann and Max Heiland and Christina Pflug and saskia kiehn",
year = "2017",
month = jun,
doi = "10.1007/s00784-016-1911-3",
language = "English",
volume = "21",
pages = "1503--1508",
journal = "CLIN ORAL INVEST",
issn = "1432-6981",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.

AU - Nienstedt, Julie Cläre

AU - Gröbe, Alexander

AU - Lebok, Patrick

AU - Büscheck, Franziska

AU - Clauditz, Till Sebastian

AU - Simon, Ronald

AU - Heumann, Asmus

AU - Sauter, Guido

AU - Möbius, Christoph

AU - Münscher, Adrian

AU - Knecht, Rainald

AU - Blessmann, Marco

AU - Heiland, Max

AU - Pflug, Christina

AU - kiehn, saskia

PY - 2017/6

Y1 - 2017/6

N2 - ObjectivesCD151 is a plasma membrane protein belonging to the tetraspanin family. CD151 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types. The present study aims to investigate the prognostic relevance of immunohistochemical CD151 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methodsTissue microarray (TMA) sections containing samples from 667 cancers of oral cavity, oro- and hypopharynx and larynx, for which follow-up data were available, were analyzed for CD151 expression by immunohistochemistry.ResultsMembranous CD151 immunostaining was recorded in 269 (60.3 %) of 446 analyzable cases. Staining was considered weak in 129 (28.9 %), moderate in 98 (22.0 %), and strong in 42 (9.4 %) of cancers. CD151 expression was unrelated to histological grade, tumor stage, nodal status, or surgical margin. There was a tendency towards a somewhat lower prevalence of CD151 expression in tumors of the oral cavity (52.9 % positive) as compared to cancers of the oro-hypopharynx (62.1 %) and larynx (63.3 %; p = 0.0100). CD151 expression had no impact on patient survival.Clinical relevanceIn summary, immunohistochemical analysis of CD151 lacks prognostic utility in HNSCC. The high prevalence of CD151 expression in HNSCC emphasizes its putative relevance as a therapeutic target for further development of anti-CD151 drugs.

AB - ObjectivesCD151 is a plasma membrane protein belonging to the tetraspanin family. CD151 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types. The present study aims to investigate the prognostic relevance of immunohistochemical CD151 expression in head and neck squamous cell carcinoma (HNSCC).Materials and methodsTissue microarray (TMA) sections containing samples from 667 cancers of oral cavity, oro- and hypopharynx and larynx, for which follow-up data were available, were analyzed for CD151 expression by immunohistochemistry.ResultsMembranous CD151 immunostaining was recorded in 269 (60.3 %) of 446 analyzable cases. Staining was considered weak in 129 (28.9 %), moderate in 98 (22.0 %), and strong in 42 (9.4 %) of cancers. CD151 expression was unrelated to histological grade, tumor stage, nodal status, or surgical margin. There was a tendency towards a somewhat lower prevalence of CD151 expression in tumors of the oral cavity (52.9 % positive) as compared to cancers of the oro-hypopharynx (62.1 %) and larynx (63.3 %; p = 0.0100). CD151 expression had no impact on patient survival.Clinical relevanceIn summary, immunohistochemical analysis of CD151 lacks prognostic utility in HNSCC. The high prevalence of CD151 expression in HNSCC emphasizes its putative relevance as a therapeutic target for further development of anti-CD151 drugs.

U2 - 10.1007/s00784-016-1911-3

DO - 10.1007/s00784-016-1911-3

M3 - SCORING: Journal article

C2 - 27444451

VL - 21

SP - 1503

EP - 1508

JO - CLIN ORAL INVEST

JF - CLIN ORAL INVEST

SN - 1432-6981

IS - 5

ER -